Mitochondrial medicine focus drives NeuroVive orphan ambitions

May 18, 2017 Christoph Graener

Underpinned by a profound understanding of genetic mitochondrial disorders, Swedish biotech NeuroVive Pharmaceutical AB is pursuing a two-pronged orphan and speciality pharma approach. CEO Erik Kinnman spoke with Scrip’s Mike Ward and explained how the company is looking for partners for its NASH and hepatocellular cancer programs but intends to develop its own orphan treatments.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Erik Kinnman – CEO, NeuroVive Pharmaceutical

Previous Article
TxCell plans first-in-man trial of regulatory T cells

Having completed a Phase I/IIa study of Ovasave, a drug candidate from its first generation non-modified an...

Next Article
vitalityDNA plans to keep healthy indviduals healthy

Precision medicines, the microbiome and a growing focus on wellness are some of the latest tools used by Lo...